Dr. Dumont serves as the Charles B. Wilson Professor and Chair of the Department of Neurosurgery at Tulane University School of Medicine. He is actually Editor-in-Chief of Vessel Plus. He is a board-certified neurosurgeon who completed his residency program training at the University of Virginia as well as a fellowship in cerebrovascular, skull base and endovascular neurosurgery at the University of Virginia. He has interests in all areas of pediatric and adult neurosurgery including spine disorders, movement disorders, epilepsy, stroke and cerebrovascular disease, peripheral nerve disease, radiosurgery and tumors of the brain and spine. He is dual-trained in open traditional microsurgery and minimally invasive endovascular surgery for vascular disorders of the brain and spine. He has active neurosurgical research interests and has published and presented extensively with more than 200 publications and more than 175 national and international presentations. He was recently elected to the Editorial Board of the Journal of Neurosurgery (the specialty's leading scientific journal) and serves on the Editorial Boards of 10 other academic journals.
Vascular neurosurgery; Cerebrovascular; Endovascular & Skull Base Surgery
Dr. Mario F. L. Gaudino is an Associate Professor of Clinical Cardiac Surgery in Weill Cornell Medical College – New York Presbyterian Hospital. He is actually Editor-in-Chief of Vessel Plus and member-in The Society of Thoracic Surgeons,The European Association of Cardio-thoracic Surgery, Società Italiana di Chirurgia Cardiaca and the surgical activities are More than 1000 adult cardiac surgery procedures performed as operating surgeon. Particular expertise in bilateral mammary and radial artery grafting for coronary artery bypass surgery. He serve as Editorial Board/reviewer for more than 49 international journals. Besides, he is author of more than 138 publications and was invited as a lecture/ speaker to deliver a speech at many national and international meetings.
Arterial conduits for coronary artery bypass surgery; Less invasive coronary surgery; Strategies for reduction of the neurological risk in cardiac surgery; Systemic effect of cardiopulmonary bypass temperature; Effect of different atrial incisions on postoperative arrhythmias; Genetic modulation of postoperative outcome; Left ventricular mass regression after aortic valve surgery: time course; determinants and prognostic implications; Acute and chronic mechanical support to circulation
Dr. Alexander N. Orekhov is the director of the Institute for Atherosclerosis Research. He is actually Editor-in-Chief of Vessel Plus and Member of the Editorial Board/reviewer of more than 49 international journals. He is a famous scientist in the field of study of atherosclerosis and the author of more than 700 scientific publications, more than 30 patents, trademarks. The number of his publications indexed in Pubmed is 349. The results of research were presented at more than 150 international scientific meetings, in some - as invited speaker.
Angiopathology; Atherosclerosis; Molecular and cellular mechanisms of human atherogenesis; Development of approaches to diagnosis; Prevention and treatment of atherosclerosis; Evaluation of clinical efficacy of the developed approaches; Translation of effective approaches into clinical practice
Dr. Verin has completed his PhD from Moscow State University, Moscow Russia and Postdoctoral studies from University of Indiana, School of Medicine. Currently he is a Professor of Vascular Biology and Medicine at Vascular Biology Center and Pulmonary Division at Georgia Regents University, Augusta, GA. He has published more than 135 papers in reputed journals and serving as an Academic Editor of Cardiology and Angiology and an Editorial Board Member in several other journals in the field of pulmonary and cardiovascular research such as Cardiovascular Pharmacology, Journal of Multidisciplinary Pathology, Journal of Vascular Diagnostics, The Journal of Biopharmaceutics Sciences, Tissue Barriers, World Journal of Respirology. In addition, he served as Editorial Board Member in American Journal of Physiology (Lung) from 2006 to 2011 and was a reviewer for a number of highly regarded journals (ex. Circulation Research, Critical Care Medicine, Physiological Reviews, PNAS).
Vascular Permeability and Cytoskeleton. The diseases associated with dysregulation of vascular barrier function such as acute lung injury and ARDS
Prof. Giuseppe De Luca is Chief of Interventional Cardiology at the Azienda Ospedaliera-Universitaria “Maggiore della Carità” in Novara, Italy. Having performed over 6,000 coronary angioplasties, Prof. De Luca is a major worldwide expert in the setting of acute myocardial infarction. He has served as member of the Scientific Committee (2010-2011) and Fellowship Committee (2015-2016) of the European Association of Percutaneous Coronary Intervention (EAPCI) and the recipient of several prestigious international scientific awards, including the Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. An author of more than 230 peer-reviewed journal publications, Prof. De Luca is Aggregate Professor of Cardiology at Eastern Piedmont University. He is Director of the University’s Laboratory of Molecular Cardiology, where he is currently conducting several studies on platelets, pharmacogenomics, genetic predisposition to atherosclerosis, thrombosis, no-reflow phenomenon, and left ventricular remodeling after STEMI.
STEMI; Platelet and antiplatelet therapies; Coronary stenting; Genetic polymorphisms; Atherosclerosis
Dr. Sobenin’s research activity is in a field of molecular and cellular mechanisms of atherosclerosis, including genetic and phenotypic markers of susceptibility; clinical, epidemiological and population studies in the field of chronic diseases with a special emphasis on atherosclerosis. Among the most notable results the following can be mentioned: the phenomenon of low density lipoprotein atherogenicity in diabetic patients; the phenomenon of multiple atherogenic modification of low density lipoprotein; the novel approaches to the development of drugs on the basis of ex vivo cell culture models; the novel algorithms of determination of cardiovascular risk on the basis of combination of genetic and phenotypic markers; an association of mutation burden of mitochondrial genome with atherosclerotic lesions in situ and predisposition to atherosclerosis in vivo; the method of determination of individual genetic predisposal to atherosclerosis and other chronic non-infectious diseases.
Molecular and cellular mechanisms of atherosclerosis
Dr. Starke is a member of the departments of neurological surgery and neuroradiology and specializes in the treatment of cerebral vascular disease including aneurysms, arteriovenous malformations and fistulas, cavernous malformaitons, moyamoya disease, carotid and intracranial stenosis including bypass surgery, pseudotumor cerebri, and intracranial hypertension. He also treats all aspects of brain tumor and skull base surgery. He is one of the few dual-trained neurosurgeons in the country able to offer both surgical and minimally invasive endovascular solutions to complex cerebrovascular disease. The minimally invasive endovascular techniques allows for patients to be treated through a 1mm incision in the leg with no incisions in the head. He also practices in gamma knife radiosurgery adding a further component of minimal invasive treatment options.
Because of his multi-modality training, he is unbiased with regards to the treatment chosen. While most lesions can be treated endovascularly, there are some cases are safer with surgery or focused radiotherapy. Dr Starke is able to perform every procedure from the initial angiogram to the final embolization or surgery. Dr. Starke also has a busy brain tumor practice, with approximately 1/3 of his patients being referred for brain tumors. He is also a specialist in pediatric vascular disease such as aneurysms and tumors, with 1 dedicated day per week treating children with endovascular techniques.
Dr. Starke is currently an Assistant Professor of Neurological Surgery and Radiology at the University of Miami MILLER School of Medicine. Previously, he graduated magna cum laude with a B.A. from Princeton University and distinction in neuroscience. He obtained his medical doctorate from Albert Einstein graduating with distinction in clinical and translational research. He also obtained a Masters of Medical Science with distinction in neuroscience research as part of the National Institute of Health Clinical Research Training Program. He also completed a cerebral vascular research fellowship at Columbia University, which provided him with a wide background in epidemiology and statistics.
Dr. Starke attended neurosurgery residency at the University of Virginia. He also completed endovascular fellowships at Thomas Jefferson University and University of Virginia and a cerebral vascular and skull base fellowship at Auckland University Hospital, New Zealand. His laboratory research focuses on cerebral vascular pathophysiology including aneurysm, AVM, ICH, and ischemic stroke models. These avenues allow for the development of novel cellular, medical, radiographic, surgical, and endovascular techniques. As the Director of Neurovascular Research, he helps run numerous clinical trials for minimally invasive treatment of cerebral vascular disease brain tumors.
Cerebral aneurysm pathogenesis; Stem cells in cerebrovascular disease; Vascular inflammation in stroke; Genetics of cerebrovascular disease; Neuroprotection; Atherosclerosis; Endovascular device & technology development; Advances in neuroimaging; Radiosurgery & minimally invasive surgery; Cerebrovascular & oncology treatment outcomes; Subarachnoid hemorrhage; Cerebral vasospasm; Intracerebral hemorrhage; Arteriovenous malformations & fistulas; Moyamoya disease & syndrome; Carotid artery disease; Pseudotumor cerebri; Idiopathic intracranial hypertension; Cerebral & skull base tumors
● CNS Research Award , Congress of Neurological Surgeons, San Diego, CA, 2016
● AANS Stereotactic and Functional Award, American Academy of Neurological Surgery, Chicago, IL, 2016.
● NSV Clinical Research Award, Neurosurgery Society Virginias, Greenbrier, VA, 2016
● CNS Research Award, Congress of Neurological Surgeons, New Orleans, LA, 2015
● Integra CNS/AANS Tumor Award, American Association of Neurological Surgeons, San Francisco, CA, 2014
● NSV Basic Science Award, Neurosurgery Society Virginias, Greenbrier, Virginia, 2014
● Galbraith Cerebrovascular Award, Congress of Neurological Surgeons, San Francisco, CA, 2013
● Brainlab Community Neurosurgery Award, American Association of Neurological Surgeons, New Orleans, LA 2013
● Crutchfield, Gage, Thomson Award, Neurosurgery Society Virginias, Greenbrier, VA, 2012
● Synthes Skull Base Award, American Association of Neurological Surgeons, Miami, FL, 2011
● Leksell Radiosurgery Award, American Association of Neurological Surgeons, Denver, CO, 2011
● Synthes Cerebrovascular Section Award, Association of Neurological Surgeons, Denver, CO, 2011
Mário César Santos de Abreu Associate Professor IV, of Faculty of Medicine, of Federal University, of Bahia – BRAZIL, grew up in Salvador –Bahia - Brazil and received his Bachelor’s (MD) degree from the Escola Bahiana de Medicina of the Catholic University of Bahia in 1980. After he obtained his specialist title of General and Cardiovascular Surgery at Heart Institute of Faculty Of Medicine of the University of Sao Paulo. During his training period work as a researcher in projects: 1. Mitral Valve Transplantation – preserved in glutharaldehyde; 2. Mechanical prosthesis at INCOR; 3. Valve re-replacement; 4. Device for protecting heart during cardiac surgery – Permutator of heat topic. And many others. Total of 19 projects. He obtained his Title of Specialist in Cardiovascular Surgery at Brasilian Society of Cardiovascular Surgery. He obtained his Ph.D. degree from the Federal University of Bahia in 1999, Thesis – New Technique for Correction of Mitral Insufficiency) he joined Professor Álvaro Rabelo at Unit of Cardiovascular Surgery at Bahiana Foundation of Cardiology at University Hospital of the Federal University of Bahia where develop projects of teaching and research, in valvular disease surgery, atrial fibrillation surgery, Jehova`s heart surgery, development of instrument for auxiliary heart valve replacement and got patent of invention. He was a visiting surgeon of Dr Denton Cooley at Texas Heart Institute, Rush- Presbyterian Hospital at Chicago, Northwestern University, Dr Alain Carpentier at Broussais Hospital ( Valvular Surgery) , Dr Stephen Colvi at Tish Hospital ( Minimally Invasive Mitral Valve Surgery), Cardiac Laser Surgery at Washington Heart Center, and many others. Participating of Florida Valve 2012, presenting a report for mitral valve surgery ( New Technique for Correction of Mitral Insufficiency, and in European Society of Cardiovascular Surgery 2014 presenting - New Technique for Correction of Atrial Fibrillation. Heart Surgeon at Hospital of Federal University of Bahia and developer of auxiliary devices for cardiovascular and trauma surgery at Cimatec – Senai - State Govern of Bahia Brasil. Patent of invention – Auxiliary Device for Cardiovascular Surgery, Registry Number PI 93092560, Privilege of Innovation. Associate Professor IV at Faculty of Medicine of Federal University of Bahia Brazil.
• 1979 - 1992 Georgian National Centre of Surgery Scientific Worker.1992 up today Research Institute of Clinical Medicine Scientific Head of Clinical Diagnostic Laboratory. Associated professor of Medical University “Hippocrates , Tbilisi. Local head of postgraduated stady pogram in Laboratory Medicine of Georgian Medical University,Tbilisi.
• Membership of Georgian Siciety of Laboratory Medicine; Georgian Federation Of Clinical Chemistry, Georgian (GAA) and European Society Of Atherosclerosis (EAS)
• State Awards Order of Honor (2012)
Clinical biochemistry; Biology; Lipidology; Molecular disorders of atherosclerosis
Prof. Wilbert S. Aronow is Professor of Medicine at New York Medical College/Westchester Medical Center, Valhalla, NY, USA. Dr. Aronow received his MD from Harvard Medical School. He has edited 14 books and is author or co-author of 1,484 papers, 340 commentaries or Letters to the Editor, and 1031 abstracts and is presenter or co-presenter of 1,392 talks at meetings. Dr. Aronow is a Fellow of the ACC, the AHA, the ACP, the ACCP, the AGS (Founding Fellow of Western Section), and the GSA. He has been a member of 127 editorial boards of medical journals, editor-in-chief of 2 journals, co-editor of 2 journals, deputy editor of 1 journal, executive editor of 2 journals, associate editor for 9 journals, and guest editor for 7 other medical journals. He has received each year from 2001-2015 an outstanding teacher and researcher award from the medical residents and from 2001-2015 from the cardiology fellows at Westchester Medical Center/New York Medical College. He has received awards from the Society of Geriatric Cardiology, the Gerontological Society of America, New York Medical College including the 2014 Chancellor's Research Award, the F1000 Faculty Member of the Year Award for the Faculty of Cardiovascular Disorders in 2011, 2013, 2014, and 2015, the Walter Bleifeld Memorial Award for distinguished contributions to clinical research from the International Academy of Cardiology in July, 2010, and a Distinguished Fellowship Award from the International Academy of Cardiology in July, 2012. He has been a member of 4 national guidelines committees including being a coauthor of the 2010 AMDA guidelines for heart failure , co-chair and first author of the 2011 ACC/AHA expert consensus document on hypertension in the elderly, a coauthor of the 2015 AHA/ACC/ASH scientific statement on treatment of hypertension in patients with coronary artery disease, and is currently a member of the 2016 ACC/AHA/ AAPA ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the management of patients with hypertension. He was a coauthor of a 2015 position paper from the International Lipid Expert Forum. He was a consultant to the American College of Physicians Information and Educational Resource (PIER) on the module of aortic stenosis. He is currently a member of the Board of Directors of the ASPC and a member of the ACCP Cardiovascular Medicine and Surgery Network Steering Committee.
Cardiology; Heart failure; Hypertension; Cardiovascular medicine and surgery
Dr. Asensio currently serves as Professor and Vice-Chairman of the Department of Surgery of Creighton University (With Tenure). He has been tenured at four other universities. He is also the Chief of the Division of Trauma Surgery and Surgical Care. He is the Director of the Trauma Center and Trauma Program and Creighton University Hospital. He is the Professor of Clinical & Translational Science Creighton University Medical School. He is also appointed as Professor of Surgery Adjunct, Uniform Services University of the Health Sciences (USUHS), F. Edward Hebert School of Medicine, Bethesda, Maryland.
Cardiovascular; Thoracic; and Complex abdominal and peripheral vascular injuries
Oleksandr Bilovol in 1985 graduated from Kharkiv Medical Institute. Medical specialties: Internal Medicine, Cardiology. In 1990 he defended the PhD-thesis, in 1999 he defended the Doctoral thesis “Clinical, pathogenic and therapeutic aspects of the neuro-humoral systems and endothelium in essential hypertension”. He is the author and co-author of publications by hypertension, diabetes and metabolic disorders.
Research of cellular; Immune-inflammatory; Neurohumoral mechanisms and the condition of endothelium during hypertensive disease; Atherosclerosis; Cardiac angina; Acute myocardial infarction; Chronic cardiac failure and their complications; Development of pathogenetic treatment
Optimization of algorithm for diagnostics of hypertension and the development of therapeutic strategies in patients with hypertension of different age groups, personalized therapeutic algorithms in comorbid conditions, including coronary heart disease, metabolic syndrome and type 2 diabetes
● Honored Doctor of Ukraine (2000)
● Order of Merit III degree (2002)
● Honored Scientist of Ukraine (2004)
● Diploma of the Cabinet of Ministers of Ukraine (2004)
● Diploma of Verkhovna Rada of Ukraine (2005)
● Corresponding member of the NAMS of Ukraine (2007)
● Order of Merit II degree (2007)
● Order of Saint Prince Vladimir II degree (2007)
● Academician of the NAMS of Ukraine (2012)
Lesya Bobronnikova in 1985 graduated from Kharkiv Medical Institute. Medical specialties: Internal Medicine. In 1992 she defended the PhD-thesis “The clinical-pathogenetic aspects and immunological disorders at patient with inflammations of the intestines in the dynamics of treatment”. In 2009 she defended the Doctoral thesis “The pathogenetic mechanisms of comorbid pathology – chronic cholecystitis and hypertension and therapeutic approach”. She is the author and co-author of publications by hypertension, chronic cholecystitis and diabetes.
Main scientific interests are related to predictors of cardiovascular risk and metabolic disorders in patients with essential hypertension and type 2 diabetes
● Member of European Society of Cardiology
● Member of European Society of Endocrinology
Dr. Bolli graduated in Internal Medicine and Cardiology from the University of Zurich(Switzerland). His main interests were in the field of hemodynamics and later in hypertension. He widened his training in hypertension under Prof. Sir Horace Smirk and Prof. Olaf Simpson and later under Prof Fritz Buhler. He published 200 articles relating to his research in hypertension. Currently, Dr. Bolli is a Clinical Professor of Medicine at McMaster University, Hamilton, Canada and a physician at the Ambulatory Internal Medicine Teaching Clinic in St. Catharines, Canada. Dr. Bolli is a Master of the American College of Physicians and served as Governor for Ontario of the American College of Physicians. Dr. Bolli is considered a pioneer in translational medicine through basic and clinical research.
Cardiovascular disease; Hypertension; Cardiology; Medicine
Graduated in Physical Education from São Paulo State University, Master in Physioterapy from the same institute and Doctor in Sciences from University of São Paulo, Brazil (Nutrition and Public Health program). Author and co-author of publications by physical activity and health, hypertention, diabetes, nutrition, aging, and healthecare costs of physical inactivity. Lecturer in São Paulo State University and Technological University of Parana State, Brazil.
Researcher in health-related themes, including nutrition, public health, chronic diseases, physical activity and aging. Reviewer in Clinics (Brazil) and currently publishing papers in International journals, lecturer in graduation (bachelor) courses in São Paulo State University and Technological University of Parana State, Brazil.
Geoffrey Burnstock is President of the Autonomic Neuroscience Centre, University College Medical School, UK. He completed a BSc at King’s College London and a PhD at University College London. He held postdoctoral Fellowships with Wilhelm Feldberg (National Institute for medical Research), Edith Bulbring (University of Oxford) and C. Ladd Prosser (University of Illinois). He was appointed to a Senior Lectureship in Melbourne University in 1959 and became Professor and Chairman of Zoology in 1964. In 1975 he became Head of Department of Anatomy and Developmental Biology at University College London and Convenor of the Centre of Neuroscience. He became Director of the Autonomic Neuroscience Institute in 1997. He was elected to the Australian Academy of Sciences (1971), Royal Society (1986), Academy of Medical Sciences (1998) and Honorary Fellow of the Royal College of Surgeons (1999) and Physicians (2000) and awarded the Royal Society Gold Medal (2000), the Copernicus Gold Medal (Ferrara) in 2009, the 2010 Gaddum Memorial Award, the Academia Europaea Erasmus Medal 2012 and the IUPS Paton Lecture 2013. He has been given Honorary Degrees in the Universities of Antwerp, Frankfurt and Leipzig. He is Editor-in-Chief of Autonomic Neuroscience (Elsevier), Purinergic Signalling (Springer), the World Journal of Pharmacology, the Journal of Diabetes Research & Clinical Metabolism and Itch & Pain. His major research interest stems from his seminal discovery of purinergic signalling and definition of P2 purinergic receptors, their signalling pathways and functional relevance. He has supervised over 100 PhD and MD students and has published over 1,530 papers, reviews and books. He was the most cited scientist in Pharmacology and Toxicology 1994-2006. His papers have been cited over 87,800 times with a Hirsch (h)-index of 138 (https://scholar.google.co.uk/citations?user=-T-OJAIAAAAJ&hl=en).
Neuroscience; Physiology; Medical neurosciences; Neurobiology; Neuropharmacology; ATP; Purinergic signalling
Brief Description of Scientific Achievements:
• Proposal and elucidation of new extracellular signalling system.
• Discovery of non-adrenergic, non-cholinergic (NANC) inhibitory nerves in the gut.
• First proposal of ATP or related nucleotide as transmitter in NANC inhibitory nerves named purinergic transmission.
• Discovery of excitation by parasympathetic nerves of urinary bladder by purine nucleotide. • Proposal of cotransmission.
• Proposal of separate postjunctional receptors for ATP and ADP (P2 purinoceptors) and adenosine (named Pl purinoceptors).
• Proposal of two types of P2 purinoceptors.
• Cloning and characterisation of the first G protein-coupled P2 receptor and P2X3 ionotropic receptor.
• Classification of P2 receptors into P2X ionotropic and P2Y metabotropic receptor families.
• Extracellular trophic actions of ATP and adenosine.
• Hypothesis for pain initiation by ATP and purinergic mechanosensory transduction underlying visceral pain.
• Purinergic signalling in embryonic development.
• Dual control of vascular tone by ATP (from perivascular nerves and endothelial cells) and long-term trophic roles of purinergic signalling in cell proliferation, migration, differentiation and death in vascular remodelling.
• Proposal for potential therapeutic targets arising from purinergic signalling in pathophysiological conditions.
Dr. Chen is currently an Associate Professor in Harvard Medical School, and a Principal Investigator and Research Associate at Vascular Biology Program in Boston Children’s Hospital. He received his PhD in cell biology from Yale University and completed postdoctoral training with Pietro DeCamilli, a premier cell biologist in the Howard Hughes Medical Institute at Yale Medical School. He was the first to discover a family of important endocytic adaptor proteins, epsins (Chen et al., Nature, 1998, Chen et al., Proc. Natl. Acad. Sci. USA, 2003, 2005 and 2009). His group developed a novel conditional epsin 1fl/fl; epsin 2-/- mouse, which has been pivotal to our continuous success by allowing characterization of the spatial and temporal roles of epsins. Using this approach, they revealed a novel function of endothelial cell-specific or lymphatic endothelial cell-specific epsins in the specific regulation of VEGF signaling through the internalization and degradation of its respective VEGFR2 or VEGFR3 receptor (Pasula, et al. JCI, 2012; Tessneer, et al. ATVB, 2014; Liu, et al. Science Signaling, 2014, Dong, et al. JCI, 2015; Rahman, et al. Circulation Research, 2016). Epsin loss dramatically impaired VEGFR2 and VEGFR3 downregulation resulting in the development of dilated and dysfunctional blood and lymphatic vascular networks, respectively. The current application builds on his expertise but expands beyond elucidating the role of epsins in angiogenesis by investigating the novel role of epsins in regulating IP3R1, LRP-1 and SR-B1 in controlling atheroma progression.
Dr. Tingjun Chen is a Research Scientist in University of New Mexico. His research field includes chronic pain, Neuro-degeneration disorders, autoimmunity disorders, etc.
Experimental ophthalmology; Neuroscience and immunology; Cellular biology; Molecular biology and pathology
Dr. Chhabra is a graduate from the University of Connecticut School of Medicine. He is currently practicing as an Invasive Non-interventional Cardiologist at the Heartland Regional Medical Center, Illinois, USA. Under the guidance of legendary Dr. David Spodick (a world famous pericardiologist), Dr. Chhabra collaborated on numerous research projects focusing on pericardial diseases in the early days of his career, and this led to his development of a special interest on this subject. Dr. Chhabra has over 135 pubmed indexed publications and has a special research interest in Pericardial diseases, Takotsubo Cardiomyopathy and Non-invasive Cardiology. He has also been a presenter and an invited speaker on several national and International society meetings.
Takotsubo cardiomyopathy; Pericardial diseases; Echocardiography; Electrocardiology; Brugada syndrome; Hypothermia; ECG abnormalities in pulmonary diseases; Aortic stenosis
Dr. Dong is a Professor of environmental epidemiology and environmental toxicology. He has years of experience working as an environmental epidemiologist in China and his research areas of focus include adults and child health, environmental health, exposure assessment, indoor and outdoor air pollution. Also, His research area focused on the toxicological evaluation of some components in PM10 and PM2.5, such as perfluorooctane sulfonate (PFOS), which exceeded levels of traditional new types of persistent organic pollutant (POPs) in ambient air particles.
The toxicological evaluation of some components in PM10 and PM2.5, such as perfluorooctane sulfonate (PFOS), which exceeded levels of traditional new types of persistent organic pollutant (POPs) in ambient air particles.
Dr. Dong is currently a senior investigator at Boston Children’s Hospital, an affiliation to Harvard Medical School. He received his PhD in Molecular Biology from the Department of Physiology and Biochemistry in 2000. His research in cardiovascular biology and metabolism is extensive. He is especially experienced in atherosclerosis from the molecular mechanism characterization and therapeutic development. He has published substantial papers in high profile journals in this field. Using Epsin mutant mice, he and his colleagues have identified the functions of epsins in several disease models, including angiogenesis models, lymphatic angiogenesis and cancers. Meanwhile, he and colleagues have developed a few therapeutic peptides in tumor angiogenesis, atherosclerosis and obesity through modulating the role of epsins in vivo and patented the interventions with Dr. Chen. He is actively investigating the molecular mechanism underlying epsin-IP3R1 interaction and ER stress signaling in endothelium in vitro and in vivo. Besides, his previous study focused on LKB1 and AMPK signaling in cardiovascular or metabolic diseases using animal model system. He has published over thirty first-author or co-author papers in the field in high impact journals including JCI, ATVB, Science Signaling, Circulation, Circulation Research, Diabetes, MCB, JBC, etc.
Cardiovascular biology and metabolism; especially experienced in atherosclerosis from the molecular mechanism characterization and therapeutic development
● Molecular regulation of vascular alpha 2C adrenoceptors
● cAMP-Epac-Rap signaling in arterioles
● (Selected) Herbs in hypertension and atherosclerosis
● (Selected) Herbs and breast cancer
● Outstanding Teaching Award, Qatar University, 2014.
● Faculty of the Year; Department of Biological and Environmental Sciences (DBES), QU. Faculty and Staff Appreciation Day; 2014
● Best Motivator with the most inspirational stories award; DBES, QU. Faculty and Staff
Appreciation Day; 2014
● Best Animated Demonstration of a Concept; DBES, QU. Faculty and Staff Appreciation Day;
● Teaching Excellence Award, College of Arts and Sciences, Qatar University, 2013.
● Postdoctoral Fellow. The Ohio State University. Davis Heart and Lung Research Institute.
Vascular Biology Division. 2004-05
● Graduate Research Assistantship. Integrated Biomedical Science Graduate Program, The Ohio
State University, Columbus, OH, USA. 2002-04.
● Graduate Research Assistantship Molecular and Cellular Biology Program, Medical College of Ohio, Toledo, OH, USA. 2000-02.
● Graduate Research Assistantship, Bowling Green State University (BGSU), Bowling Green, OH, USA. 2000.
● Graduate Teaching Assistantship, BGSU, Bowling Green, OH, USA.1999-2000.
● Graduate Teaching Assistantship, American University of Beirut, Beirut-Lebanon. 1998.
● Dean’s Honor List. Faculty of Arts and Sciences, American University of Beirut, 1997.
● Dean’s Honor List. Faculty of Arts and Sciences, American University of Beirut, 1995.
● Fellow of the European Society of Cardiology since 2010.
● Young Investigator Award 2009 of the European Society of Cardiology.
● Editorial Member of the Revista Española de Cardiologia since 2012.
● Coordinator of several national registries on coronary heart disease and acute coronary syndrome.
Bu-Lang Gao, a professor of mediccal sciences at Shijiazhuang First Hospital, Hebei Medical University, grew up in China and received his Bachelor’s degree from Hebei Medical Univesity. After working in hospitals as a doctor for 13 years, he went to study and obtained his Master’s degree in Kunming Medical University in 2004 and Ph.D in Shanghai Jiaotong University in 2007. On obtaining his Ph.D in 2007, he went to do postdoctor research in Tufts Univesity Medical Center in Boston, USA. Upon completing his postdoc research and later medical research in Tufts University, he was invited back to China and hired as a professor at Shijiazhuang First Hospital, Hebei Medical University. During these years of medical research, he has published over 70 scientific papers including over 50 SCI-indexed papers. He was the first to report the results of systematic research of endovascular intervention in the treatment of hyperthyroidism and was the first to propose the mechanism of diseases of arterial expansion including arterial aneurysms and arteiral expansion following stenosis. He is currently engagged in the research of exploring the mechanisms of these arterial diseases including coronary artery stenosis (coronary heart disease), aortic aneurysms, aortic dissection, cerebral aneurysms, cerebral artery stenosis, carotid artery stenosis, and aneurysms or stenosis of peripheral arteries.
Interventional treatment of vascular diseases including cerebral aneurysms, animal experiments for medial research, computational fluid dynamics analysis for studying vascular diseases like cerebral aneurysms and vascular stenosis; medical statistics analysis
● The outstanding graduate of 2001-2002 during my study for master’s degree in Kunming Medical College
● The third award of “English Speech Contest of Scientific Paper Report” in the 7th National Congress of Interventional Radiology in 2006 in China
● The second award of outstanding graduate scholarship during 2005-2006 in Shanghai Jiaotong University in China
● The first award of outstanding graduate scholarship during 2006-2007 in Shanghai Jiaotong University in China
● Outstanding graduate of Shanghai city in 2007 in China
● First prize in the scientific paper contest in NanHua University with the paper entitled Angiographic Follow-up of Cerebral Aneurysms Treated with Guglielmi Detachable Coils (GDCs) ：An Analysis of 162 Cases with 173 Aneurysms.
● AOCR Fellowship in the 11th Asian Oceanian Congress of Radiology held in Hong Kong on 6-9 August 2006
● Outstanding undergraduate of Hebei Medical University in 1987
Dr. Gutsaeva is an Assistant Professor in the Department of Ophthalmology at Augusta University. She earned her PhD from St. Petersburg State University, St. Petersburg, Russia and completed her postdoctoral training at the Russian Academy of Science and Duke University Medical Center. Dr. Gutsaeva is the recipient of multiple NIH, private foundations, and pharmaceutical industry grants.
Vascular inflammation; Molecular mechanisms of endothelium-blood cell adhesive interactions; Signaling pathways involved in pathological neovascularization
Mariann Harangi MD, PhD is an Associate Professor at Department of Internal Medicine at University of Debrecen, Faculty of Medicine, Debrecen, Hungary. She is specialized in treatment of primary and secondary lipid disorders with particular focus on familial hypercholesterolemia and statin intolerance.
Dr. Harangi received her medical degree from University of Debrecen in Hungary, and she also earned a doctorate degree (PhD) from University of Debrecen. She carried out a one-year post-doctoral training period at University of Regensburg, Regensburg, Germany. She is board certified in Internal Medicine, and Endocrinology and Metabolism by the Hungarian Board of Internal Medicine.
Dr. Harangi is the General Secretary of the Hungarian Atherosclerosis Society and member of several professional organizations, including International Atherosclerosis Society. She authored numerous peer-reviewed publications in distinguished journals such as Clinical Endocrinology, Obesity Reviews and Cerebrovascular Disease. Dr. Harangi is a member of the editorial board of Disease Markers.
Inherited abnormalities of lipid metabolism; Familial hypercholesterolemia; Statin intolerance; Prevention and treatment of atherosclerosis; HDL structure and function
Prof. Walid M Hassan, MD, is the Cardiovascular Disease (Cardiology) Specialist in Pasadena, Texas. He attended and graduated with honors from medical school in 1985, having over 31 years of diverse experiences, especially in Cardiovascular Disease (Cardiology). He affiliates with many hospitals including Bayshore Medical Center. Dr. Walid M Hassan also cooperates with other doctors and physicians in medical groups.
Percutaneous coronary/Vascular/Valvular and structural intervention; Percutaneous aortic and pulmonary valve implantation (TAVI/TPVI) / Aortic aneurysm endovascular repair (EVAR)/ Renal denervation/ EndoVenous laser ablation (EVLT); Diabetic heart disease
Platelet aggregation; Inflammation; Cell therapy; Coronary flow and physiology
Prof. Hassan is a member of 45 International Scientific Societies and Associations, an editorial board member or a reviewer for 32 International Journals. The total of his publication (published articles/ abstracts/ presentations) is 560.
2010.09-2013.06, Fudan University Shanghai Cancer Center, Ph. D.
2013.06-2015.09, Sun Yat-sen University Cancer Center, Post-doctoral
2015.09-current, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Associate Research Fellow
Evidence-Based medicine (Meta-Analysis); Molecular biology; Oncology; Cancer epidemiology; Molecular epidemiology
Dr. Shijun Hu is a Professor in Soochow University and Deputy Director of Institute for Cardiovascular Science of Soochow University. He is member of the Editorial Board/reviewer of more than 30 international journals, including Vessel Plus.
Stem cells; Cardiac regeneration; Disease modeling; Cardiovascular research
Dr. Hu has his own laboratory at Institute for Cardiovascular Science, Soochow University. And more information about his research activities can access at http://hulab-ics.suda.edu.cn/en/.
Cardiovascular diseases; Diabetes; Hyperlipidemia; Chromatography; Atherosclerosis; FPLC; Ultracentrifugation ; Fluorescence spectroscopy; Lipoproteins; HPLC; Cell culture; Western blotting; siRNA; Enzymatic assays; Data management; Protein purification; Lipid analysis; qPCR; Scientific writing; Mentoring and tutoring
● Awarded Research Scholar Award, Postdoctoral Research Fellowship Supplement, and Pilot Project Grant by the SUNY Downstate Medical Center
● Awarded Licensed Innovations for Excellence in “Innovation, Creation & Discovery” by the State University of New York
● Awarded Research Fellowship by ICAR, Government of India
● Granted US patent for Compositions and Methods for Treating Hyperlipidemias
● Secured independent research funding from the American Heart Association
● Editorial Commentary on IRE1β and atherosclerosis in International Atherosclerosis Society
The research interest is directed towards identifying P2X and P2Y receptors as novel therapeutic targets by:
1) Defining the pharmacological properties of P2X and P2Y receptors;
2) Characterising the physiological roles of ATP and P2X receptors in neurotransmission;
3) Determining the pathophysiological functions of P2X and P2Y receptors in dysfunctional urinary bladder, pulmonary arterial hypertension and chronic pain.
1987 The American Physiological Society (GI Section). Best presentation
1989 Beit Memorial Research Fellowship for Medical Research
1994 The Physiological Society. Northwest Travelling Fellowship
1997 Caledonian Research Foundation - Biomedical Support Research Fellowship
1999 British Pharmacological Society - Bill Bowman Travelling Lectureship
2013 Fellow of the British Pharmacological Society
Dr. Kennedy is a Senior Lecturer at Glasgow University and has been involved in developing and using in vivo animal models of balloon injury and stenting for around 15years. He has published widely using these models to investigate mechanisms of cardiovascular pathophysiology. He has chaired symposia at local and international meetings and organized several specialized meetings on in vivo research. He is on the editorial board of the British Journal of Pharmacology and the review journal Pharmacology & Therapeutics and is a member of the British Pharmacological Society meetings committee. His work is supported by the British Heart Foundation, Medical Research Council and the EPSRC. His laboratory is one of the few in Europe which uses the pig model of coronary stenting.
Current Areas of Research:
● Atherosclerosis and Modified Lipids
● Stent-based Drug Delivery
● Effect of Hypoxia on Sphingolipids
● AMPK and Vascular Pathology
List of Publications:
Dr. Tarek Khater worked as research assistant participating in the ROAD Project, "AMDEC" sponsored by the NIH, which evaluate the effects of a school-Based Intervention Program on Risk Factors for Type II diabetes and Obesity in middle school age children. It was a joint project between Endocrine Pediatrics & Behavioral Pediatrics Departments. He worked in both departments assisting a Research Assistant coordinating the project including dealing with Principle Investigator, Pharmaceutical companies, nursing research staff, data enter using Data capture system and all aspects of the project. Having direct interact with patients, obtaining history, doing physical examination, writing the clinical notes, order investigations, obtaining the results, discussing it with the attending(s), present oral case presentations and discuss diagnosis and management plan with the Pediatrics Endocrinology Department team. He worked in Endocrine Pediatrics Genetics Lab. working on DNA extraction & PCR.
1. Poster Presentation
Khater, Tarek R.. (July, 2003). Premarriage Checkup In Egypt Poster presented at: XIX International Congress of Genetics; Melbourne, AUS.
Khater, Tarek R... (February, 2006). Premarriage Counseling Poster presented at: National coalition of Health Professional Education in Genetics NCHPEG; Bethesda, MD, USA.
2. Oral Presentation
Khater, Tarek R... (February, 2004). Telemedicine Facilitating Premarital Bioinformation Oral Presentation
presented at: Euro-Mediterranean Internet-Satellite Platform Health Medical Education & Research (EMISPHER), International Dissemination; Cairo, EGY.
3. Peer Reviewed Online Publication:
Khater, Tarek R... (2003, February 02). Premarriage checkup in Egypt (Multiple articles on search engine on British Medical Journal) BMJ Electronic, during 2001 to 2006.
Dr. Anirban Kundu is presently working as Consultant Cardiac Surgeon at National Heart Institute, New Delhi. This is a premier centre for the treatment of heart diseases, having been established in 1981 as the first private sector cardiac hospital in India. Dr. Kundu’s interests are off pump total arterial myocardial revascularisation and heart failure surgery.
Internal medicine (general medicine); Cardiology; Cardiothoracic surgery
Dr. Lau completed his undergraduate studies at New York University where he obtained degrees in Philosophy and Psychology. He then earned his medical degree at Downstate Medical Center, where he was recruited to stay to complete his General Surgery residency. During this time, he received multiple awards including the Thomas W. Pollock Award for professionalism, compassion and dedication. Subsequently, he completed his Cardiothoracic Surgery Fellowship at Weill Cornell Medical College, New York Presbyterian Hospital, and Memorial Sloan Kettering Cancer Center. He then remained at Weill Cornell for an Advanced Cardiovascular/Aortic Aneurysm Surgery Fellowship and was recruited to stay on staff as an Attending Cardiothoracic Surgeon and Assistant Professor of Cardiothoracic Surgery at New York Presbyterian – Weill Cornell Medical Center.
Thoracic aortic surgery; Cardiac surgery; Coronary bypass; Arterial conduits; Valve repair/replacement surgery; Cerebral protection strategies during aortic surgery; Thoracoabdominal aneurysms; Aortic root surgery and physiology
Dr. Lavie graduated from Louisiana State University Medical School in 1983 and completed internal medicine residency at Ochsner and fellowship in cardiovascular diseases at Mayo , where he joined the faculty in 1989. Dr. Lavie is Professor of Medicine and Medical Director, Cardiac Rehabilitation and Preventive Cardiology; Director, Exercise Testing Laboratory; and Staff Cardiologist, Echocardiographic Laboratory at the John Ochsner Heart and Vascular Institute in New Orleans, Ochsner Clinical School-The University of Queensland School of Medicine and he previously served for 10 years as Associate Director of the Internal Medicine Training program. He served as a Consultant in the Department of Preventive Medicine at the Pennington Biomedical Research Center in Baton Rouge, Louisiana from January 2012-October 2014. Dr. Lavie’s research interests include cardiac rehabilitation and prevention, lipids, hypertension, obesity, and exercise, as well as noninvasive testing, encompassing echocardiography, exercise testing, and nuclear cardiology. He is the author of nearly 1000 medical publications including two cardiology textbooks, and over 50 book chapters. Dr. Lavie serves as a frequent lecturer, reviewer for several medical journals, and is Associate Editor and Cardiovascular Section Editor of theMayo Clinic Proceedings and is Editor in Chief of Progress in Cardiovascular Diseases and serves on the Editorial Boards of the Journal of the American College of Cardiology, American Journal of Cardiology, Journal of Cardiopulmonary Rehabilitation Prevention, and over 20 other Journals. For 2011 till now, he has served as Chairman of the Document Oversights Committee for AACVPR. For the years 2003 and 2004 he served as Chairman of Vascular, Hypertension and Prevention for the American College of Cardiology and he has been an elite reviewer for JACC for 7 of the last 8 years, also receiving the Simon Dack Award as a life-time, hall of fame, reviewer.In 2013, he gave Key-Note lectures for both the American College of Sports Medicine and the Cardiac Rehabilitation one for the AACVPR, where he received the 2013 Research Award. From a personal stand-point, he is an avid sports fan and competitive runner, with personal records in the 5K, 10K, Half-Marathon and Marathon of 18:30, 38:30, 1:24:30, and 3:10, respectively. He is the author of “The Obesity Paradox” , released April,2014.
Cardiac rehabilitation and prevention; Lipids; Hypertension; Obesity; and Exercise; Noninvasive testing; Encompassing echocardiography; Exercise testing; Nuclear cardiology
Dr. Aurelio Leone was born in Roma, Italy on July 21, 1942. He is a Physician and Researcher. He had his first job at the Pathological, Anatomy Institute of The University of Roma, Italy. In 1969 he worked as a Medical Researcher in Pisa, Italy, at the CNR Institute of Clinical Physiology and then as a clinical Cardiologist in La Spezia, Italy, from 1973 to 1985. Director of the Medical Division of Pontremoli City Hospital, Italy, from 1985 to 1999. He was chief of the Department of Internal Medicine of City Hospital in Massa, Italy, from 1999 to 2002. At present, he is an independent researcher, fellow of the Royal Society for Promotion of Health, London, UK (FRSPH), and Fellow of the American Society of Hypertension (FASH), as well as member of the World Heart Federation (WHF).
Graduated in Biological Sciences (Biomedicine) and qualification in Clinical Analyzes. Master's Degree in Medical and Biological Sciences, Doctorate in Sciences, Postdoctoral degree from the Institute of Biomedical Sciences. It received financial support from CNPq (Universal Announcement - 455326 / 2014-
2) for research (until November 2017). At moment, I am currently an Associate Professor in the Department of Health Sciences at “Universidade Federal de Lavras (UFLA)”, Brazil. I have experience in the field of physiology, biochemistry, cellular and molecular biology, working mainly on the following topics: hyperglycemia (diabetes), hypoxia (cardiac ischemia), ovarian hormone deprivation and physical exercise, with emphasis on skeletal and cardiac muscle remodeling.
Hyperglycemia (diabetes); Hypoxia (cardiac ischemia); Ovarian hormone deprivation and physical exercise, with emphasis on skeletal and cardiac muscle remodeling
2015 Best E-poster presented at Socesp Department of Physical Education, XXXVI Congress of the Society of Cardiology of the State of São Paulo
2014 Honorable Mention - XI ENCOUNTER OF SCIENTIFIC INITIATION, Uninove
2012 Honorable Mention, XX Congress of the Brazilian Society of Hypertension
2010 Honorable Mention, Federation of Societies of Experimental Biology - FeSBE
2004 Honorable Mention, Federation of Societies of Experimental Biology FeSBE
Dr. Myasoedova was a coordinator in Russian research group of multicentre study: “Mechanisms of accelerated atherosclerosis in HIV-infected patient”. Dr. Myasoedova have participated in two double-blinded placebo-controlled trials on atherosclerosis regression, and in another trial on antiatherosclerotic efficacy of Karinat in postmenopausal women, as PI of the study. Dr. Myasoedova is certified for performing ultrasound examination and monitoring of carotid atherosclerosis for the international IMPROVE Study. In the field of basic research, Dr. Myasoedova have investigated the gender differences in the processes of intracellular cholesterol accumulation and the role of sex hormones in cellular and molecular mechanisms of atherogenesis, and have work on research project of association of mitochondrial mutations with atherosclerosis development and risk. Dr. Myasoedova have participated in more than 10 international symposia for the last 5 years and have presented the obtained results. In the last period, Dr. Myasoedova follow the research projects in cardiac surgery. Dr. Myasoedova have participated as a research assistant in the "Omega-3 fatty acids for prevention of post-operative atrial fibrillation" clinical trial. Dr. Myasoedova is coordinator in the clinical trial “Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing CABG and/or Aortic Valve Surgery (ASABYVALV)” and in the “Steroids In caRdiac Surgery Trial” (SIRS). Dr. Myasoedova have participated as a coordinator in “Mitroflow Real Time Registry” project and “Polyphemus: Administration of polyphenol rich supplement and early midterm outcomes after cardiac surgery”.
Neurology and pathophysiology; Atherosclerosis
Main Fields of Surgical Activity:
- Coronary artery disease and surgical revascularization (coronary artery bypass grafting)
- Heart valve repair surgery - Surgery of aneurysms of the aortic root and ascending aorta
- Simultaneous Hybrid Revascularization of Carotid and Coronary Artery Atherosclerotic Disease
- Surgery of Heart Failure
Fields of Active Research:
- Anticoagulant treatment in the immediate postoperative period in patients subjected tovalve replacement with a bioprosthetic valve
- Evaluation of long-term results of surgical repair and replacement of the aortic root, of surgical treatment of the heart failure and of surgical repair of the mitral valve
- Role of non-invasive diagnostic tools (cardiac CT) in cardiac surgery
Narasimham L. Parinandi (Pari) is an Associate Professor in Department of Internal Medicine of The Ohio State University College of Medicine, Columbus, OH. He earned his PhD (1980-1986) from the University of Toledo, Toledo, OH. He did his postdoctoral fellowship (1986-90) at the Hormel Institute, a premier lipid institute of the University of Minnesota. He was also a faculty research scientist at the Johns Hopkins University School of Medicine (1998-2002). He was the Chair of Education of the Davis Heart Lung Research Institute of the Ohio State University. He has published nearly 120 peer-reviewed papers including original research papers, book chapters, and edited books on Free Radicals and Antioxidant Protocols and Mitochondria in Lung Health and Disease. He has teaching and mentoring experience for more than 35 years and mentored over 75 students, post-doctoral fellows, and junior faculty members. He was also an editor of the Toxicology section of the Chemical Abstracts Service of the American Chemical Society (1990-98). He also serves as a reviewer for nearly 75 peer-reviewed journals in the areas of biochemistry, cell biology, toxicology, pharmacology, and lipidology. Dr. Parinandi is a reviewer of the grants of the National Institutes of Health, Department of Defense, and other non-profit organizations and foreign institutions and funding agencies. He has been on the editorial board of the Cell Biochemistry Biophysics (Springer), Molecular Biology Reports (Springer), World Journal of GI Pharmacology, and Journal of Glycomics & Lipidomics. Dr. Parinandi teaches basic, advanced, and applied biomedical sciences including physiology & cell biology, oxidative stress, drug discovery, and membrane biophysics and biochemistry. He received many awards like the Distinguished Mentor Award of the Davis Heart & Lung Research Institute of the Ohio State University Wexner Medical Center in 2008 and the Distinguished Undergraduate Mentor Award of the Ohio State University Undergraduate Research Program in 2009.
Lipidomics approach of studying the regulation of phospholipases under oxidative and nitrative stress in the vascular endothelium and respiratory tract epithelium; Lipid signaling mechanism of inflammatory cytokine release in respiratory epithelium exposed to inhaled toxicants; Heavy metal toxicity to endothelial and epithelial systems and membrane lipid signaling; Synthesis, analysis, and biological activity of oxidized phospholipids, oxylipid signal mediators, oxidized sugar and lipid conjugates; Lipid mediators in adipose during sleep apnea; Phospholipidomics and eicosanomics of chronic lung diseases; Analytical Lipid Biochemistry
Currently, Dr. Campos is a Group Leader at the University Hospital of Santiago de Compostela in the Department of Neurology involved in the study of cerebrovascular diseases.
He did his PhD in Neuroscience at the University of Vigo (Spain) in 2006. During this period he worked in the role of neuronal nicotinic receptors on the dopamine and glutamine release in the nigro-striatal system by means of in vivo experimental techniques.
After his PhD period, he worked during two years as postdoctoral researcher at the Institut d’Investigacions Biomèdiques of Barcelona (IIBB) (Spain) where he was working in the in vitro neurotoxic effect (oxidative damage and glutamate excitotoxicity) induced by environmental pollutants.
In 2009 he moved toward a more translational research and he joined to the Department of Neurology of the Clinic University Hospital at the Santiago de Compostela to work in the Clinical Neurosciences Research Laboratory with the aim to participate in the search of new therapies against neurological disorders as stroke.
Between 2011 and 2012, as research fellow, he was working in the Neuroscience Center at Massachusetts General Hospital-Harvard Medical School under the supervision of Prof. Michael Moskowitz and Dr Christian Waeber with the purpose of improve his skills in the field of experimental neurosciences. In collaboration with Dr. Waeber, they described by means of a new ischemic stroke animal model, the protective efficacy of Fingolimod/FTY720 (Gilenya®, Novartis) and they suggested the use of this drug to reduce the risk of brain hemorrhage after thrombolytic treatment (published in Stroke journal). The use of fingolimod as candidate drug for stroke has also become in hot topic in the field of cerebrovascular diseases.
In 2013, he moved again to Department of Neurology of the Clinic University Hospital at the Santiago de Compostela as independent researcher involved in the management of the in vitro and in vivo experimental unit of the Clinical Neurosciences Research Laboratory.
Currently, as Group Leader, he have an active collaboration with Sun Pharmaceutical Industries Ltd (India) and Weizmann Institute (Israel) with the aim test the protective effect of the recombinant human enzyme GOT in animal models of cerebral ischemia in order to obtain experimental evidences for a posterior clinical trial in stroke. The protective activity of this enzyme is based on its capability to reduce the excitotoxic damage of glutamate after stroke. In line with this project, he is also involved in the study and development of nanocarriers for cerebral drug delivery with the aim to improve the efficacy and increase the therapeutic window of GOT in stroke.
He is also working in the thrombolytic efficacy of encapsulated tPA in sono-sensitive nanostructures and vectored toward the region of the thrombus in ischemic model animals. tPA works by dissolving the clot and improving blood flow to the part of the brain being deprived of blood flow, however its use in clinical practice is limited to a narrow therapeutic window due to hemorrhagic transformation risk. Therefore, his porpoise is to use of tPA encapsulated in eco-sensitive structures and the subsequent release by ultrasound in the arterial occluded which would allow to enhance the thrombolytic efficacy and reduce adverse effects of this treatment. This novel strategy is being probed in in two models thromboembolic cerebral ischemia, a distal occlusion model that mimic the small vessel embolic occlusions, and proximal occlusion model that mimic the large artery embolic occlusion.
In other of my projects, he is testing the protective effect of hypothermia in stroke and the potential molecular mechanisms involved with this therapeutic approach. Hypothermia is the most effective protective therapy for brain ischemia, but its use in stroke is limited due to serious side effects. His group have described that focal brain hypothermia (selective application of hypothermia to the region of cerebral ischemia) is able to induce same protective efficacy than systemic hypothermia that represents a promising and non-stressful alternative for hypothermic treatment (these results are under review in Brain journal). Currently, in collaboration with Dr. Sven Wellmann (University of Basel) they are working in role of RBM3 (RNA-binding motif protein 3) as this proteins seems to be participate in the protective of hypothermia.
Finally, he have opened a new interesting line of investigation based in the development of Induced Pluripotent Stem cells (iPS cells) from patients with cerebrovascular diseases. In collaboration with Prof. Dell'Era Patrizia (Italy), they are working in the derivation of iPSCs cells from blood cells of CADASIL patients. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy or CADASIL is an archetypal small vessel disease of the brain caused by dominant mutations in the NOTCH3 receptor with high risk of stroke and migraine symptoms for patients. Vascular smooth muscle cell has been identified as the primary target cell in this disease, however the pathophysiological processes leading from NOTCH3 mutations to smooth muscle cell loss remain poorly understood. Therefore, their propose is to study these mechanisms by reprogramming blood cells to stem cells (iPSCs9 and then differentiating them to vascular smooth muscle cells and analyze the characteristic features of CADASIL.
Blood brain barrier permeability; Cerebral hemorrhage; Cortical spreading depression; Cerebrovascular diseases; Drug devolvement; Glutamate excitoxicit; Induced pluripotent stem cells (iPSCs) for modeling diseases; Mesenchymal stem cells (MSCs); Migraine; Neurodegenerative diseases; Neuroprotection; Stroke; Translational research
Atherosclerosis; Thrombosis ; Vascular Disease
As principle investigator, she directed project of a mechanical research on cholesterol-overloaded induced by dysfunction of high-density lipoprotein particles from National Natural Science Foundation of China (2016.01-2019.12), project of mechanism research on lipid and glucose metabolism in mediation of atherosclerosis from the Beijing Outstanding Young Scholars Program (2015.01-2017.12). As project manager, she participated in the project of mechanism research on very low-density lipoprotein (VLDL)-VLDL receptor pathway in regulation of atherosclerosis from National Natural Science Foundation of China (2012.01-2015.12).
Research on etiology of cardiovascular disease; Molecular mechanisms of atherosclerotic cardiovascular disease and cardiovascular risk factors
Current Research Interests:
Lay in the area of pulmonary hypertension induced cardiovascular pathology; with a specific focus on molecular mechanisms of uncontrolled vascular cell proliferation; inflammation; oxidative stress; fibrosis
Recent Research Targets:
1) Covalent oxidation of EGFR and nitration of Akt and their role in pulmonary vascular remodeling
2) Nitration and oxidation induced eNOS uncoupling in endothelial dysfunction development
3) Novel pro-inflammatory properties of anti-oxidant protein peroxiredoxin 1 (Prx1) induced by Prx1 oxidation
4) Redox state of HMGB1 and its role in mechanisms of HMGB1 signaling
Dr. Leonardo Roever was graduated in 2002, had his specialization in Unifesp (2003), Masters degree in Health Sciences from the UFU (2008). Editor in Chief - Evidence Based Medicine and Practice and Quality in Primary Care. Academic Editor of Medicine (USA - Baltimore, Maryland - Impact Factor - 2.133). Editor-in-Chief of Research Topics: Cardiac Remodeling: New Insights in Physiological and Pathological Adaptations of Frontiers in Physiology (Impact Factor - 4.031) in Switzerland, Special issue entitled: Coronary Artery Disease (Journal of Cardiovascular Diseases & Diagnosis). Executive Editor of Atherosclerosis: Open Access. Editorial board member of the Journal of Epidemiology, Internal Medicine, Translational Medicine, Cardiovascular Diseases & Diagnosis, Interventional Cardiology, Emergency Medicine and others. Reviewer journals such as British Medical Journal (BMJ), Circulation, European Heart Journal, JACC, JAMA Internal Medicine, Stem Cells, Nature (EJCN), Stroke, Neurology, Chest, Critical Care Medicine, Circulation: Heart Failure‏, JACC: Cardiovascular Interventions, JACC: Cardiovascular Imaging, Circulation: Cardiovascular Interventions, JAHA, The American Journal of Medicine, The American Journal of Sports Medicine and others. Ad Hoc is the American Heart Association (AHA-USA) and the National Institute of Health (NIH-USA). The total of publications comprises 104 articles in journals specialized as an author and/or co-authored, 19 abstracts in conference proceedings, and 2 international book chapter.
Evidence based medicine and practice; Network meta-analysis; Randomized controlled trials; Systematic reviews and meta-analysis; Umbrella reviews; Meta-epidemiologic studies; Cross-sectional studies; Atherosclerosis; Ectopic adiposopathy; Biomarkers; Inflammatory markers; Metabolic syndrome; Coronary artery disease; Cardiovascular prevention; Heart failure; Hypertension; Arrhythmia; Clinical epidemiology; Clinical research; Biostatistics; Aging and development of new diagnostic and therapeutic methods
Dr. Nabi Shah earned a BS in Pharmacy form University of Karachi in 2006-2007 and a PhD in Pharmacology (Pharmacogenetics, Pharmacogenomics and Pharmaco-epidemiology) from University of Karachi in 2013. In October, 2013 Dr. Shah joined COMSATS Institute of Information Technology as Assistant Professor of Pharmacology. He worked as a postdoctoral fellow with Professor Colin NA. Palmer at Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, UK from 2014-2016, and resumed CIIT in 2016.
Dr. Shah is working in collaboration with Pakistan Risk Of Myocardial Infarction Study (PROMIS), Risk Assessment of Cerebrovascular Events study (RACE), Pakistan Type-2 Diabetes Study, and Genetics of Diabetes and Audit Research Tayside Study (GoDARTS) and GOSHARE, Scotland, UK.
Dr. Shah’s lab specializes is in population genetic research and currently studying the genetic basis for susceptibility to common diseases such as type 2 diabetes, heart disease, stroke and asthma. He has published 15 papers in top journals including papers in Nature Genetics and the Journal of the American College of Cardiology. These papers have been cited by over 1000 other studies worldwide.
Dr. Shah’s current studies involve using the electronic medical register to link patient outcome to genomic information, including GWAS and next generation sequencing data. This will provide new drug targets for the prevention and treatment of such diseases and will also allow for more informed and personalized usage of current therapies.
Pharmacology (Pharmacoepidemiology; Pharmacogenetics and Pharmacogenomics)
Anna Shalimova in 2005 graduated from Kharkiv National Medical University. Medical specialties: Internal Medicine, General Practice - Family Medicine. In 2010 she defended the PhD-thesis “The mechanisms of the development chronic heart failure in patients with chronic kidney disease”. In 2016 she defended the Doctoral thesis “The role of genetic, hemodynamic and metabolic mechanisms in the development of comorbid pathology – essential hypertension and type 2 diabetes”. She is the author and co-author of publications by hypertension and diabetes indexed in Pubmed and SCOPUS. Now she is responsible for research work in Clinical Pharmacology Department at Kharkiv National Medical University.
Main scientific interests are related to comorbid pathology, genetic aspects of hypertension and type 2 diabetes, metabolic syndrome, individualization of antihypertension therapy
Member of International Society of Hypertension, European Society of Cardiology, European Society of Endocrinology, European Society of Atherosclerosis.
- Young Investigator Fellowships 83rd EAS Congress (March 22–25, 2015, Glasgow, UK)
- Meeting grant ECE 2015 (May 16–20, 2015, Ireland, Dublin)
- Meeting grant ECE 2016 (May 28–31, 2016, Munich, Germany)
- Journal of Endocrinology Travel Grant ECE 2016 (May 28–31, 2016, Munich, Germany)
- Accommodation grant ESH 2016 (June 10–13, 2016, Paris, France)
- Alberto Ferrari Poster Prize ESH 2016 (June 10–13, 2016, Paris, France)
- Travel grant ISH 2016 (September 24–29, 2016, Seoul, Korea)
- Global Health Travel Award winner Keystone Symposia J3: Diabetes, and J4: Obesity and Adipose Tissue Biology (Jan 22–26, 2017, Keystone, Colorado, USA)
Dr. Siniscalchi is a medical doctor, Clinical specialist (neurologist) and responsible of Rare Disease in Neurology and responsible of Cerebrovascular disease and Neurosonology in the Department of Neuroscience, Neurology Division and Stroke Unit “Annunziata” Hospital – Cosenza, Italy. He is adjunct professor at the Department of Pharmacology Department of Experimental Medicine, Faculty of Medicine, University of Catanzaro "Magna Graecia". Dr. Siniscalchi is author and co-author of scientific publications in neurology and neuropharmacology. Scientific publications have been cited by various authors in medical journals with impact factor international bibliography of international scientific books. Previously scientific publications arising from studies abroad as a postdoctoral fellowship research at the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University - Montreal (Canada). In the latter case, the researches were conducted in collaborations with the Neurology Clinic, University of Rome "Tor Vergata", Neurorehabilitation Hospital IRCCS "S. Lucia, Rome and the Department of Physiology, Laboratory of Neurophysiology University of Rome "Tor Vergata". Furthermore, recent scientific publications are collaborations between Department of Neuroscience, Neurology Division “Annunziata” Hospital – Cosenza with the Neurological Clinic of the University of Rome "Tor Vergata" and IRCCS Rehabilitation Hospital "S. Lucia, Rome and with the Clinical Pharmacology, Department of Experimental Medicine, Faculty of Medicine, University of Catanzaro "Magna Graecia".
Neurology; Cerebrovascular disease and neurosonology; Expert on intravenous tissue-type plasminogen activator for the treatment of acute cerebral ischemiain the "Stroke Unit"
Dr Cristiano Spadaccio is a cardiothoracic surgeon at the Golden Jubilee National Hospital in Glasgow, UK and an Honorary Clinical Lecturer at the University of Glasgow in the College of Medicine Veterinary and Life Science affiliated to the Institute of Cardiovascular and Medical Sciences. He graduated as medical doctor at the University Campus Bio-Medico of Rome in 2006. He obtained and completed a postdoctoral training at the University of Pittsburgh Medical Center at the department of Cardiovascular Surgery and at the McGowan Institute for Regenerative Medicine where he was dedicated to stem cell differentiation, 3D culture using bioresorbable scaffolds and development of 3D systems for stem cells differentiation. He obtained his PhD degree at the University La Sapienza of Rome in 2009 working on tissue engineering of heart, vessels, bone and muscles. He has also been associate visiting investigator at the unit of translational medicine and research at the universitary hospital Dr Negrin, Spain where he dedicated to the in vivo application of bioresorbable scaffolds for cardiovascular translational purposes. He is also among the founders of a biomedical engineering company involved in regenerative medicine named Biomatica Ltd.
From the clinical point of view Dr Spadaccio is dedicated to minimally invasive cardiac surgery for both the aortic and mitral valve and to off-pump techniques for coronary surgery. He is also interested in transcatheter procedures for aortic and mitral valve and in the development of medical devices and alternative access routes to cardiovascular structures, as testified by his clinical research activities. He is also the coordinator of several international clinical studies involving coronary and valve surgery.
His basic science research activity is focused on several themes related to stem cells differentiation, tissue engineering and regenerative medicine with particular attention to biofunctionalization of resorbable materials for tissue regeneration and to translational aspects of tissue engineering. Considering his expertise in cardiovascular surgery, he developed clinically translatable small and large animal models of cardiac and vascular disease focusing on the application of biomaterials and drug delivery systems in routine clinical scenarios. In this context, his experimental efforts, raised from several collaborative activities with other groups, led to the production of a functionalized-heparin releasing scaffold for vascular replacement, a functionalized myocardial patch for ventricular restoration, a bioresorbable device for sternal synthesis after cardiac surgery and several tissue engineering-based approaches for diabetic wound repair. He is also focused on the study of the biological properties of the extracellular matrix and on the development of ECM-like biological surrogates to stimulate tissue regeneration, in particular using electrospinning techniques. Additionally, he dedicated to the elucidation of several biomolecular aspects of cardiovascular degenerative and inflammatory diseases and to the identification of markers of pathologies through proteomic approaches.
He scientific and clinical activity is testified by several papers published on international peer reviewed journal and presented his results in a number of international society meetings including the American College of Cardiology, the American Association for Thoracic Surgery, The European Association for Cardiothoracic Surgery, the International Society of Minimally Invasive Cardiothoracic Surgery, the International Society of Stem Cells research, The American Society of Artificial Organs in USA, the Tissue Engineering and Regenerative Medicine Society in Europe and the International Cardiac BioAssist Association in Singapore. He has applied for international grants related to his work sponsored by NIH and other institutions. He organized cooperative consortia for research projects with many research groups. He is currently the lead guest editor for a supplement of the Journal Drug Target Insights focused on drug delivery devices, guest Editor for and serves as reviewer for both clinical and biomedical journals.
Cardiac surgery; Minimally invasive aortic and mitral surgery and surgical devices; Myocardial revascularization (off pump surgery, incomplete revascularization); Mitral valve disease; Tissue engineering and biomaterials and regenerative medicine; Stem cells differentiation and cell therapy; Clinical applied proteomic analysis; Molecular basis of inflammation in atherosclerosis; Biostatistics; Immunology in cardiovascular disorders
● Chitwood Award ISMISC Montreal 15-18th June 2015
● John Parker Medal at the Society of Cardiothoracic Surgery UK for best presentation
● Honorary clinical lecturer at University of Glasgow in the College of MVLS affiliated to the Institute of Cardiovascular and Medical Sciences.
● Consultant and collaborator in funded research grant sponsored by University Campus Bio-Medico of Rome Young Investigator Project Title: Towards tissue prototyping: fabrication of patient-specific scaffolds for regenerative medicine.
● Three times member of the committee for PhD thesis defense evaluation in the department of Biomaterials and Bioengineering at University Campus Bio-Medico of Rome
● Invited Lecture Biomimetic and biofunctionalization approaches in cardiovascular tissue engineering for stem cells differentiation: getting closer to nature, getting closer to patient University of Padova Padua Muscle Regerative Days
● Invited lecture Politecnico di Torino May 2011 “Biomateriali ed ingegneria tissutale in medicina rigenerativa cardiovascolare: avvicinarsi al letto del paziente” (Biomaterials and tissue engineering in cardiovascular regereative medicine: getting closer to patient’s bed)
● Best oral presentation SIB (Italian society for biomaterials) May 23th-25th 2011
● Best oral presentation AISAL (Italian society of laboratory animal sciences) Sept 22th-23th.
● Lead guest editor for supplement in the Journal Drug Target Insights. Title Current developments in drug eluting devices
Pro. Jianxin Sun is Associate Professor of Medicine in Thomas Jefferson University. He is the member of American Heart Association, American Physiological Society, American Society for Biochemistry and Molecular Biology, American Society of Microbiology and International Society for Heart Research (ISHR). He has published 50 papers in reputed journals and serving as the reviewer of Circulation Research, Circulation, Diabetes, Apoptosis, Cancer Res, AJP-Heart and Circulatory Physiology, British J of Pharmacology, Journal of Pharmacology and Experimental Therapeutics, Journal of Molecular and Cellular Cardiology, PLos One; Faseb, Ageing, BMC-genomics and Molecular and Cellular Biology.
Vascular inflammation; Endothelial dysfunction; Nuclear receptor; Heart failure
1.Role of Orphan Nuclear Receptor 4A family (NR4A) in Vascular Homeostasis. In addition to studying nitric oxide signaling, his laboratory has made a major contribution to our understanding of molecular mechanisms that regulate NR4A receptors and their functional significance in vascular inflammation and remodeling. Their lab explored the mechanisms underlying vascular inflammation and subsequently identified orphan nuclear receptor Nur77 as a key regulator for inhibiting endothelial cell activation. Their preclinical studies suggest that this compound has potent beneficial cardiovascular effects without obvious evidence of toxicity. These pioneering studies led to a rapid growth in the field of NR4A receptors that has implications for several diseases including cardiovascular disease, pulmonary disorders, and cancer.
2.Regulation of Endothelial Nitric Oxide Synthase (eNOS) in Endothelial Cells: Endothelium-derived nitric oxide (NO) is an important regulator of vascular function. Their early scientific training and publications focused on the regulation of eNOS expression and activity in vascular endothelium and its relevance to endothelial dysfunction. This discovery has important implications in understating the mechanisms underlying endothelial dysfunction associated with many cardiovascular diseases.
Dr. Tinkham has been a registered nurse for 18 years, with experience in Perioperative and Wellness nursing. She holds a Bachelor’s of Science in Nursing with a minor in psychology, as well as a Master’s of Science in Healthcare Administration and another in Nursing Education. She is in process of a PhD in Animal Behavior. She holds certifications in perioperative nurse, cardiac rehabilitation, and public health as well as numerous certifications in holistic health topics. She has published over 30 peer reviewed articles and continuing education pieces and presented at several professional conferences, as well as being a editorial board member of AORN.
Perioperative and Wellness nursing
•Clarice Woodward Excellence in Writing award 2009,2010
•Cambridge Who’s Who among Healthcare Professionals and Executives 2009, 2011
•National Association of Professional Women Inductee 2010
•National Woman of Worth nominee 2009, 2010
•Nurse Week Nursing Excellence Award nominee 2009,2010
•AORN Award of Excellence Clinical Poster 2010
•2010 Florence Nightingale award- Riverside Community Hospital
•Society for Vascular Nursing Clinical Excellence in Vascular Nursing Award 2010
•AORN Connections “Member making a difference” June 2010
•AORN Outstanding Achievement in Volunteerism 2011
•California State Legislature 2011 Notable Nurse Award
•2011 Global Professional Network Who’s Who Registry Among Executives, Professionals and Entrepreneurs
Prof. Wang is associate professor in Thomas Jefferson Unveristy. She graduated as PhD on molecular biology at Shanghai Jiao Tong University. Her research investigates the signaling mechanisms responsible for adipokine-mediated cardiovascular protection, with the ultimate goal of identifying new therapeutic targets at the molecular, cellular, and organ level in in vivo animal models, for the purpose of ameliorating cardiovascular complications caused by type-2 diabetes.
Cardiovascular injury and protective strategy; Heart failure and development of new diagnostic and therapeutic methods; Etiology of cardiovascular disease; Molecular mechanisms of atherosclerotic cardiovascular disease and cardiovascular risk factors
Discovered the Critical Role of Caveolin(s) in Trans-Membrane Signaling and Cardiovascular Protection, and its Contribution to Cardiac Injury when Impaired during Diabetes. Diabetes blocks the cardioprotective response to multiple endogenous prosurvival molecules and exogenous interventions, increasing mortality. The molecular mechanisms leading to “universal” impairment of cardioprotective signaling in the diabetic heart remain unclear. Caveolins (Cav) serve as scaffolding regulators of signaling proteins. Many signaling molecules bind to Cav and compartmentalize within caveolae, forming signaling complexes. Our series studies demonstrated for the first time that carveolin-centered signal complex formation is impaired (signalsome dissociation) in diabetic cardiovascular tissue, blocking cardioprotective signaling and contributing to diabetic cardiovascular injury.
Prof. Webster’s research for the past 20 years has focused on hypoxia, animal models of ischemia, angiogenesis, programmed cell death, gene and stem cell therapy for cardiovascular disease, cancer therapeutics, atherosclerosis, and more recently micro-RNA, aging, obesity, diet research and type 2 diabetes. He have published more than 150 papers in these areas. As director of the Vascular Biology Institute at the University of Miami he have established in-house capabilities and/or access to a wide array of advanced equipment, technology and expertise and created a state-of-the-art vascular research facility to efficiently address questions in vascular disease and treatment. His focus areas include apoptosis, acute myocardial infarction, gene and stem cell therapy for ischemic disease (PAD and CAD) and molecular mechanisms of insulin resistance associated with obesity and type 2 diabetes. An important aspect of this work has been our characterization of hypoxia-regulated AAV gene therapy and combination gene and stem cell therapy in mouse and rabbit models.
He have been continuously funded for 25 years by multiple NIH grants as well as AHA and State funding including the Florida Heart Research Institute, Agatston Research Institute and Miami Baptist Hospital.
Apoptosis, acute myocardial infarction, gene and stem cell therapy for ischemic disease (PAD and CAD) and molecular mechanisms of insulin resistance associated with obesity and type 2 diabetes
Internal medicine; Non invasive cardiology; Invasive cardiology; Invasive angiology; Intensive care medicine
• Poster price, German Society of Internal Medicine (1995)
• Award, American Heart Association (1996)
• Oskar Lapp Price, German Cardiac Society (1998)
As first author or first co-author, Dr. Shang Xie have published internationally 9 papers in the past two years. He was invited to give presentations two times in international conferences of Melbourne (2015.10) and Beijing (2016.01). He has acted as an international reviewer for Scientific Reports, Gene, Oral Oncology, Medicine, Oncotarget, Clinical Implant Dentistry and Related Research, International Journal of Oncology, Oncology Reports, Journal of Cancer, Cancer Investigation, etc. Besides, he has acted as an international section editor (Head and Neck) for Translational Cancer Research, Annals of Translational Medicine.
Evidence-based medicine; Head and neck neoplasms; Microsurgical reconstruction; Stomatology/Dentistry
Dr. Emre Yalcinkaya was graduated and received his MD from Gulhane Military Medical Academy, School of Medicine (Turkey) in 2006. After his four-year fellowship at the Department of Cardiology of Gulhane Military Medical Academy, Yalcinkaya was assigned as a Specialist in Cardiology in 2013. Became an ESC Fellow (FESC) in 2014. Awarded with ESC 2015 Training Grant to practice in Electrophysiology at Zurich University Hospital for a year. He now practices as a Electrophysiology Fellow in Zurich University Hospital (Switzerland). As a clinician and clinical scientist, Yalcinkaya is member of numerous national and international working groups.
M. Yaroustovsky is the author of 270 scientific papers, 7 monographs and books. M. Yaroustovsky has developed a technique of correcting molecular composition of the blood in infants being on prolonged cardiopulmonary bypass for anemia, hypoproteinemia, and electrolyte and acid-base balance correction. M. Yaroustovsky has scientifically substantiated and introduced into clinical practice modern methods of correction and maintenance of molecular composition of blood in critically ill patients, undergone heart and vascular surgeries, such as hemofiltration, albumin dialysis, high-volume plasmapheresis, selective haemoperfusion and etc. Under his supervision, the studies, focused on the efficacy of endotoxin selective haemosorption based on using modified nanotechnology cartridges in septic patients, have been conducted. M. Yaroustovsky has demonstrated the possibility of selective correction of dyslipidemia with modern extracorporeal haemocorrection methods that reduces progression of atherosclerotic process and prevents recurrence of heart and brain ischemia.
Intensive care patients after cardiovascular operation
Shui-Qing Ye, MD,PhD, is a Professor and William R. Brown/Missouri Endowed Chair in Medical Genetics and Molecular Medicine in Department of Biomedical and Health Informatics and Department of Pediatrics, University of Missouri Kansas City School of Medicine and The Children’s Mercy Hospital. He is also the Director, Division of Experimental and Translational Genetics and Core of Omic Research at The Children’s Mercy Hospital. Dr. Ye’s current and growing research interests include an application of Translational Bioinformatics to leverage big data to make new biological discoveries and gain new unifying global biological insights, which may lead to the development of new diagnostic and therapeutic targets for human diseases, a dissection of genetic components of complex human diseases such as ARDS, CAD, CKD, drug induced liver injury using omics technologies, an investigation of roles and mechanism of Nicotinamide Phosphoribosyltransferase (NAMPT) in human physiology and pathology.
Big data analysis for biomedical discovery, application of omic technology to dissect genetic components of complex diseases, roles and mechanisms of NAMPT in human diseases
1. Honorary Professor, Wuhan University School of Medicine, Wuhan, Hubei Province, China 2016
2. Visiting Professor, Tangdu Hospital, Fourth Military Medical University, Xian, Shanxi Province,China2016
3. Distinguished lecturer, Department of Physiology, The University of Oklahoma, Health Science Center, Oklahoma City, OK, USA2008
4. Honorary Professor, Department of Biochemistry, Wuhan University School of Medicine, (Formerly, Hubei Medical College), Wuhan, Hubei Province, China1999
5. Biographee, The Marquis Who'sWho® (New Jersey, USA) in Science and Engineering 1998-1999
6. Biographee, International Biographical Centre (Cambridge, England) 1999
7. Young Investigator Award, American Heart Association, USA 1994
8. Young Investigator Award (Finalist), The Xth International atherosclerosis Symposium, Montreal, Canada1994
9. Travel Award, for attending” The Aspen Bile Acid /Cholesterol Conference", Aspen, Colorado, USA1991
10. Graduate Fellowship (full tuition exemption and stipend), Department of Pathology University of Chicago Pritzker School of Medicine, Chicago, IL, USA1989-1993
11. Graduate Fellowship (full tuition exemption and stipend), Department of Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA1988-1989
12. Third-class Award, Excellent Research Thesis in Natural Science,Science and Technology Association of Wuhan, Wuhan, Hubei Province, China1985
Zhao is a Professor of Solid Mechanics at Wolfson School of Mechanical, Electrical and Manufacturing Engineering of Loughborough University. He holds a PhD in Solid Mechanics (1996) and a BEng in applied mechanics (1992), awarded by Xi’an Jiaotong University, one of the top and prestigious universities of China. Zhao has been continuously working onStructural Integrity of gas turbine engines, focusing on deformation, facture, fatigue, creep, crack initiation and growth for nickel-based superalloys. In this high impact area, he has secured, as lead/principal investigators, research funding worth 2.2 million pounds. He received the award of prestigious Royal Society-Leverhulme Trust Senior Research Fellowship in 2008. He has an outstanding and sustained record of high-quality peer-refereed journal publications, including International Journal of Plasticity, Journal of the Mechanics and Physics of Solids, Materials Science and Engineering A and Engineering Fracture Mechanics. Zhao is specialised in Solid and Computational Mechanics, with original fundamental contributions to crystal plasticity and visco-plasticity constitutive modelling, fatigue and creep through many years of persistent research at top UK universities. He has been invited for organizing mini-symposiums, key note speeches and also guest lectures by a series of international conferences. In particular, Zhao has been successful in developing new research in the area of stent Biomechanics, with publications in Materials Science and Engineering C and Journal of Biomechanics. The research is funded the British Heart Foundation (a charity organization), in collaboration with both Abbott USA and Lucidoen UK.
Mechanical performance of polymeric bioresorbable vascular scaffolds; Computational modelling of stent biomechanics and its design; Fracture; Fatigue and creep of advanced materials; Dislocation; Crystal plasticity and cyclic viscoplasticity models for metallic materials; Oxidation-assisted fatigue and creep crack initiation and propagation; Multi-scale material model (discrete dislocation; Crystal plasticity and continuum plasticity); Mechanical behaviour of biodegradable polymers for stent application; Residual stress and its effect on failure in polymer composites; Thermal shock stress and fracture
● Chartered Engineer, Institution of Mechanical Engineers, UK
● Royal Society-Leverhulme Trust Senior Research Fellowship, 2008-2009
● List of publications: http://publications.lboro.ac.uk/publications/all/collated/mmlz.html
Dr. Zhou received his Ph.D. from the University of California, Irvine. He performed postdoctoral work at the University of Washington and the Rockefeller University before joining the faculty of the University of Kentucky. Dr. Zhou is currently the Director of Center for Metabolic Disease Research and an Associate Professor in the Department of Pharmacology and Nutritional Sciences at the University of Kentucky. He has published more than 30 papers in reputed journals and has been serving as an editorial board member in several other journals.
Cardiovascular disease; Obesity; Metabolic disorders; Lipid homeostasis; Endocrine disrupting chemicals; Nuclear receptors
● List of publications: http://med.uky.edu/users/czh229